Compare Marathon Digital Holdings Inc (MARA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Repligen Corporation Common Stock — how do they compare? Marathon Digital Holdings Inc trades at $8.1 (market cap $3.52B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.2× Marathon Digital Holdings Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Digital Holdings Inc for 22 Days and Repligen Corporation Common Stock for 0 Days on average.
| MARA | RGEN | |
|---|---|---|
Market Cap | $3.52B | $11.14B |
Volume | 36,018,511 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $22.84 | $194.57 |
52-Week Low | $6.73 | $102.87 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.56B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Digital Holdings (MARA) trades at $9.11, down 3.5% on the day, reflecting ongoing volatility amid mixed technical signals. The stock shows bearish momentum in moving averages but bullish oscillators, with key resistance at $10. Fundamentally, the company reported significant losses with a net income margin of -429.71% in 2026, though valuation ratios appear attractive with P/E of 3.37. Recent news highlights continued analyst coverage and Bitcoin-related sector movements influencing stock performance.
MARA presents a high-risk opportunity with analyst consensus price target of $13 offering 43% upside potential, balanced by 45% buy and 45% hold ratings. However, persistent negative earnings, cash flow challenges, and Bitcoin market dependency create substantial risk. Investors must weigh the discounted valuation against the company's inability to achieve profitability despite revenue generation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
